Cargando…
Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort
PURPOSE OF REVIEW: This review highlights the problem of neuropsychiatric adverse effects (AEs) associated with elexacaftor/tezacaftor/ivacaftor (ETI), current suboptimal mitigation approaches, a novel testable mechanistic hypothesis, and potential solutions requiring further research. RECENT FINDIN...
Autores principales: | VanElzakker, Michael B., Tillman, Emma M., Yonker, Lael M., Ratai, Eva-Maria, Georgiopoulos, Anna M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552811/ https://www.ncbi.nlm.nih.gov/pubmed/37655981 http://dx.doi.org/10.1097/MCP.0000000000001014 |
Ejemplares similares
-
Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database
por: Mehta, Zumi, et al.
Publicado: (2021) -
Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design
por: Jain, Raksha, et al.
Publicado: (2022) -
Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies
por: Bresnick, Kathryn, et al.
Publicado: (2021) -
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
por: Bessonova, Leona, et al.
Publicado: (2018) -
Intestinal current measurement and nasal potential difference to make a diagnosis of cases with inconclusive CFTR genetics and sweat test
por: Minso, Rebecca, et al.
Publicado: (2020)